Diligence memo · auto-generated · as of July 2, 2026
Orbis Biosciences, Inc
Orbis Biosciences, Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Orbis Biosciences, Inc operates in Biotech / Pharma, based in Lenexa.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Orbis Biosciences, Inc has raised $1.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $985K on 2016-10-17.
Most recent recorded round closed around 2016-10-17.
Valuation (modeled)modeled
Provath models Orbis Biosciences, Inc at approximately $50M (range $538K–$571M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.81× the median modeled value of Pre-Seed Biotech / Pharma companies in 2016–2018 (12 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 45 months.
Last raise 9.7 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 32% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: Nexion Biosciences Inc, Synereca Pharmaceuticals, Inc., Novome Biotechnologies, Inc., Me Biosciences, Inc., Continuum Biosciences, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.